Recent Articles

CRCHD Announces New CURE Distinguished Scholars Seminar Series

| June 21, 2017 | 0 Comments

CRCHD Announces New CURE Distinguished Scholars Seminar Series In celebration of 21 years of the Continuing Umbrella of Research Experiences (CURE) program, CRCHD is pleased to announce a new scientific seminar series, the CURE Distinguished Scholars Seminar Series. See Original Article

Continue Reading

Celebrating 21 Years of the CURE Program

| June 21, 2017 | 0 Comments

Celebrating 21 Years of the CURE Program In honor of the 21st anniversary of the Continuing Umbrella of Research Experiences (CURE) program, CRCHD will host “Celebrating 21 Years of the CURE Program” on June 27, 2017.See Original Article

Continue Reading

FDA Approves Pembrolizumab for Tumors with Specific Genetic Features

| June 20, 2017 | 0 Comments

FDA Approves Pembrolizumab for Tumors with Specific Genetic Features FDA approved pembrolizumab for patients with solid tumors that have specific genetic features, called mismatch repair deficiency and high microsatellite instability. This is the first approval based on a genetic feature, rather than cancer type.See Original Article

Continue Reading

Abiraterone Improves Survival for Some Men with Hormone-Sensitive Prostate Cancer

| June 19, 2017 | 0 Comments

Abiraterone Improves Survival for Some Men with Hormone-Sensitive Prostate Cancer In two large clinical trials, adding the hormone-blocking drug abiraterone to androgen-deprivation therapy (ADT) allowed men with metastatic hormone-sensitive prostate cancer to live longer than men who were treated with ADT alone.See Original Article

Continue Reading

Trastuzumab Emtansine Improves Survival in Previously Treated Metastatic HER2-Positive Breast Cancer

| June 14, 2017 | 0 Comments

Trastuzumab Emtansine Improves Survival in Previously Treated Metastatic HER2-Positive Breast Cancer Two clinical trials show that trastuzumab emtansine (T-DM1) improves survival compared with other standard treatments for patients with HER2-positive metastatic breast cancer that has progressed after treatment with other HER2-targeted drugs.See Original Article

Continue Reading

Genomic Study Seeks Clues to Help Explain Breast Cancer Disparities

| June 13, 2017 | 0 Comments

Genomic Study Seeks Clues to Help Explain Breast Cancer Disparities Using one of the largest collections of tumor samples from African Americans with breast cancer, researchers tried to assess the extent to which the molecular characteristics on these tumors might help to explain breast cancer disparities. See Original Article

Continue Reading

CAR T Cells: Expanding into Multiple Myeloma

| June 12, 2017 | 0 Comments

CAR T Cells: Expanding into Multiple Myeloma Results from two early-phase trials presented at the American Society of Clinical Oncology suggest that an immunotherapy using genetically engineered immune cells may be effective in patients with advanced multiple myeloma.See Original Article

Continue Reading

Special Spotlight: 2014 AACR Conference: The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

| June 9, 2017 | 0 Comments

Special Spotlight: 2014 AACR Conference: The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved A focus of the 7thAACR annual conference was community engagement and how to attract and retain racial and ethnic populations. Three community health educators from CRCHD’s National Outreach Network program delivered presentations in this area.See Original Article […]

Continue Reading

Biomarker Test Could Reduce Unnecessary Biopsies to Detect Prostate Cancer

| June 9, 2017 | 0 Comments

Biomarker Test Could Reduce Unnecessary Biopsies to Detect Prostate Cancer Findings from a new study show testing for two biomarkers in urine may help some men avoid an unnecessary biopsy to detect a suspected prostate cancer.See Original Article Enzymology of GTP-competitive RAS inhibitors RAS molecules have affinities for GTP and GDP that are in the […]

Continue Reading

Powering Off Cancer

| June 9, 2017 | 0 Comments

Powering Off Cancer The uncontrolled growth of cancers is dependent on altered metabolism. For example, many cancers are highly dependent on the altered metabolic reactions that occur in their mitochondria. New therapies that target these reactions are being tested.See Original Article No Magic Bullet for RAS Kevin Haigis discusses the complicated natural histories of the […]

Continue Reading